A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus
Latest Information Update: 23 Aug 2022
At a glance
- Drugs Retatrutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 19 Aug 2022 Status changed from active, no longer recruiting to completed.
- 11 Mar 2022 Planned End Date changed from 10 Jan 2022 to 15 Dec 2022.
- 11 Mar 2022 Planned primary completion date changed from 10 Jan 2022 to 15 Dec 2022.